利拉鲁肽与甘精胰岛素治疗初诊2型糖尿病的疗效及安全性比较

Efficacy and Safety Comparison of Liraglutide and Glargine in Newly Diagnosed Type 2 Diabetes

试验以对比利拉鲁肽与甘精胰岛素分别联合二甲双胍对初诊为2型糖尿病患者血糖控制效果及其安全性为目的。将60例初诊为2型糖尿病患者随机分为两组,予以利拉鲁肽(1.2u/d)及甘精胰岛素(0.3u/kg.d)分别联合二甲双胍(1g,Bid)治疗8周,比较治疗前后的血糖、糖化血红蛋白等指标。结果显示两组治疗后血糖、糖化血红蛋白均明显减低(P<0.05);利拉鲁肽组低血糖发生率明显低于甘精胰岛素组(P<0.05);而该组治疗后体重及收缩压下降,与胰岛素组有明显差异(P<0.05)。故对糖尿病患者,利拉鲁肽与甘精胰岛素同样有效控制血糖,而利拉鲁肽能够明显降低体重及收缩压,并且低血糖发生率更低。

To compare the efficacy and safety of adding Liraglutide to Metformin with addition of Glargine to Metformin in subjects newly diagnosed type 2 diabetes. In this 8--week 60 enrolled subjects newly diagnosed Type 2 Diabetes were ran- domly assigned to once--daily Liraglutide （1.2 u/day injected subcutaneously）, to Glargine （0.3u/kg ~ d injected subcuta- neously）. All treatments were in combination therapy with Metformin （lg twice daily）. Results show that the two groups of blood sugar and glycated hemoglobin were significantly reduced after treatment （P〈0.05）. The incidence of hypoglyce- mia, Liraglutide group was obviously lower Glargine group （P〈0.05）. And the group after treatment weight and systolic blood pressure drops,and insulin group had significant difference （P〈0.05）. Therefore, in patients with diabetes, once-- daily Liraglutide induces similar glycemic control, reduces body weight, declines SBP and lowers the occurrence of hypoglycemia compared with Glargine.